Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
FORT LAUDERDALE - Pediatrix Medical Group, Inc. (NYSE:MD), a healthcare company with a market capitalization of $1.36 billion, announced Monday that its Board of Directors has authorized a $250 million share repurchase program for the company’s outstanding common stock. According to InvestingPro data, the company’s stock has delivered an impressive 54% return over the past year.
The program has a three-year term and will be implemented based on various factors including market price, business conditions, legal requirements, and alternative investment opportunities, according to the company’s press release.
"In view of our strong cash flow, current and forecasted cash balances and relatively low debt levels, our Board has authorized a $250 million share repurchase program, which we plan to use opportunistically," said Mark S. Ordan, Chair of the Board and Chief Executive Officer. The company’s robust financial position is reflected in its 17% free cash flow yield and healthy current ratio of 1.8, as reported by InvestingPro.
The physician services provider stated that repurchases may be executed through privately negotiated transactions or open market transactions, potentially including trading plans under Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934.
Pediatrix indicated it intends to execute the program in alignment with its capital allocation strategy that prioritizes investment for long-term business growth. The company noted the program may be suspended or discontinued at any time.
Pediatrix Medical Group provides physician services with approximately 4,400 affiliated physicians and clinicians specializing in obstetrics, maternal-fetal medicine, neonatology, and various pediatric subspecialties. The company maintains a strong financial health score of "GREAT" according to InvestingPro, which offers comprehensive analysis and additional insights through its detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, Pediatrix Medical Group reported strong earnings for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.53, exceeding the forecasted $0.42, and reported revenue of $468.84 million, slightly above the anticipated $464.37 million. UBS responded to this outperformance by raising its price target for Pediatrix Medical Group to $16.50, while maintaining a Neutral rating. Meanwhile, Jefferies adjusted its price target to $19.00 from $21.00, citing concerns over eAPTC, although it maintained a Buy rating due to strong quarterly results. Pediatrix Medical Group’s recent performance has also allowed the company to raise its fiscal year 2025 EBITDA guidance by $20 million at the midpoint. These developments highlight the company’s robust financial health and strategic adjustments in response to market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.